Volume 11, Number 8—August 2005
Research
Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use
Table 2
FQ use | FQ-R P. aeruginosa |
MRSA |
|||||
---|---|---|---|---|---|---|---|
Total FQ | Levofloxacin | Ciprofloxacin | Total FQ | Levofloxacin | Ciprofloxacin | ||
1999 | R2 | 0.525 | 0.593 | 0.233 | 0.392 | 0.644 | 0.255 |
p | 0.008 | 12 | 0.116 | 0.029 | 0.0017 | 0.0937 | |
n | 12 | 0.003 | 12 | 12 | 12 | 12 | |
2000 | R2 | 0.397 | 0.285 | 0.519 | 0.617 | 0.617 | 0.112 |
p | 0.004 | 0.019 | 0.348 | 0.0001 | 0.0001 | 0.175 | |
n | 19 | 19 | 19 | 18 | 18 | 18 | |
2001 | R2 | 0.481 | 0.335 | 0.067 | 0.318 | 0.32 | 0.159 |
p | 0.001 | 0.009 | 0.2821 | 0.018 | 0.018 | 0.1134 | |
n | 19 | 19 | 19 | 17 | 17 | 17 | |
2002 | R2 | 0.178 | 0.112 | 0.09 | 0.267 | 0.28 | 0.145 |
p | 0.056 | 0.137 | 0.184 | 0.019 | 0.017 | 0.097 | |
n | 21 | 21 | 21 | 20 | 20 | 20 | |
2003 | R2 | 0.104 | 0.012 | 0.01 | 0.157 | 0.02 | 0.001 |
p | 0.16 | 0.641 | 0.66 | 0.092 | 0.538 | 0.9924 | |
n | 20 | 20 | 20 | 19 | 19 | 19 |
*Linear regression of fluoroquinolone (FQ) use versus percent resistance for hospitals. R2, coefficient of determination; n, number of hospitals. Bold indicates significant relationships (p<0.05). FQ-R P. aeruginosa, fluoroquinolone-resistant Pseudomonas aeruginosa; MRSA, methicillin-resistant Staphylococcus aureus.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.